Cipla

Quick check

The five things to look at first. Open one for more.

• DebtHighest safetyRated AAA by 2 agencies.
• ResultsProfit fallingIn the Jun 2026 quarter, sales rose 2.3% and profit fell 39% from a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 29% of the company, about the same as in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 30.2 times its yearly earnings (P/E), pricier than 75% of the time in the last 5 years. Its usual P/E is about 29.

Cipla against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)30.2 against a typical 33.2: cheaper than most peers (1st = cheapest).103rd of 220
• Sales growth+2.3% against a typical +15.6% from a year earlier.144th of 197
• Profit growth−39.2% against a typical +18.9% from a year earlier.126th of 160
• Share price, 3 months−8.4% against a typical −2%.132nd of 200
• Size₹ 1,08,010.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).4th of 199

Exchange filings and their impact on the company.

• 27 Oct 2026Outcome of Board MeetingMedium impactNegativePrice −0.4% that day
  Q2 FY27 results filed; run-rate points to flat sales with continued margin and profit pressure.

  Cipla's board on 27 October 2026 approved unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026, with auditors giving an unmodified limited review conclusion. The filing also repeats the long-running NPPA pricing dispute disclosure of Rs 2,011 crore (principal Rs 863 crore plus interest) with no provision, and notes a small ESOP allotment to 80.79 crore shares. With sales running around Rs 7,100 crore per quarter, the results point to broadly flat revenue with profitability still below the FY25 peak.

  Full analysisFiling
• 23 Oct 2026General UpdatesLow impactPositivePrice +0.5% that day
  Cipla's US InvaGen plant cleared routine FDA inspection with zero observations.

  Cipla said the US FDA inspected its wholly-owned InvaGen Pharmaceuticals facility in Hauppauge, New York from 19 to 22 October 2026. The inspection was a routine cGMP inspection and concluded with zero Form 483 observations. This confirms compliance at the US site and supports uninterrupted supply and future approvals from the facility.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Achin Gupta

Global Chief Executive Officer, Managing Director, Executive Director

Ashish Adukia

Global Chief Financial Officer

Rajendra Kumar Chopra

Compliance Officer, Company Secretary